Commitments and Contingencies- Additional Information (Details) - USD ($)				3 Months Ended
	Jan. 10, 2025	Nov. 07, 2024	Jul. 03, 2024	Mar. 31, 2025
Forecast
Loss Contingencies [Line Items]
Percentage of common stock shares outstanding				20.00%
Merger Agreement
Loss Contingencies [Line Items]
Merger agreement date		Nov. 07, 2024
Subsequent Event | Convertible Promissory Note
Loss Contingencies [Line Items]
Debt instrument, issued, principal amount	$ 3,750,000
Subsequent Event | Convertible Promissory Note | Maximum
Loss Contingencies [Line Items]
Debt instrument, issued, principal amount	7,500,000
Kalaris Therapeutics, Inc. | Merger Agreement
Loss Contingencies [Line Items]
Termination fee required to pay		$ 3,480,000
Termination fee required to receive		10,410,000
Kalaris Therapeutics, Inc. | Merger Agreement | Forecast
Loss Contingencies [Line Items]
Termination fee required to pay				$ 3,480,000
Termination fee required to receive				10,410,000
Kalaris Therapeutics, Inc. | Maximum | Merger Agreement
Loss Contingencies [Line Items]
Required to pay costs and expenses		580,000
Kalaris Therapeutics, Inc. | Maximum | Merger Agreement | Forecast
Loss Contingencies [Line Items]
Required to pay costs and expenses				$ 580,000
Kalaris Therapeutics, Inc. | Subsequent Event | Additional Permitted Bridge Financing
Loss Contingencies [Line Items]
Debt instrument, issued, principal amount	3,750,000
Kalaris Therapeutics, Inc. | Subsequent Event | Additional Permitted Financing
Loss Contingencies [Line Items]
Receive an additional permitted financing	7,500,000
Remaining receive an additional permitted financing	3,750,000
Kalaris Therapeutics, Inc. | Subsequent Event | Convertible Promissory Note
Loss Contingencies [Line Items]
Debt instrument, issued, principal amount	3,750,000
Kalaris Therapeutics, Inc. | Subsequent Event | Convertible Promissory Note | Additional Permitted Bridge Financing
Loss Contingencies [Line Items]
Debt instrument, issued, principal amount	3,750,000
AlloVir | Forecast
Loss Contingencies [Line Items]
Percentage of common stock shares outstanding				20.00%
AlloVir | Maximum | Merger Agreement
Loss Contingencies [Line Items]
Required to pay costs and expenses		$ 580,000
AlloVir | Maximum | Merger Agreement | Forecast
Loss Contingencies [Line Items]
Required to pay costs and expenses				$ 580,000
AlloVir | Subsequent Event | Additional Permitted Financing
Loss Contingencies [Line Items]
Remaining receive an additional permitted financing	3,750,000
AlloVir | Subsequent Event | Convertible Promissory Note | Maximum
Loss Contingencies [Line Items]
Debt instrument, issued, principal amount	$ 7,500,000
Stockholder Derivative Lawsuit
Loss Contingencies [Line Items]
Loss contingency, name of plaintiff			Steffens
Loss contingency, date of dismissal			Nov. 04, 2024